Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma
Thoracic Cancer · 2024-03 · 15 (8) · 622-629
DOI: 10.1111/1759-7714.15232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 05.02.2024. Verfasst von Li Chao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation, The Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital.
Abstract (Originalsprache)
Background
To evaluate the safety and efficacy of camrelizumab plus albumin paclitaxel and carboplatin in the neoadjuvant treatment of borderline resectable or unresectable locally advanced esophageal cancer.
Methods
A retrospective analysis was conducted on 27 patients with borderline resectable or unresectable locally advanced esophageal cancer who received neoadjuvant treatment with camrelizumab plus albumin paclitaxel and carboplatin at Shanxi Cancer Hospital from January 2020 to March 2022. Of these, 20 patients underwent thoracoscopic esophagectomy after neoadjuvant treatment.
Results
Overall, 88.9% (24/27) of patients completed neoadjuvant treatment. The objective response rate was 79.2% (19/24) according to the RECIST criteria. Of the 20 patients who underwent surgery, the R0 resection rate was 95%, and 35% (7/20) achieved pathological complete response (pCR). During neoadjuvant treatment, 30% (6/20) of patients experienced grade ≥3 treatment‐related adverse events (TRAEs), and 20% (4/20) had grade ≥3 postoperative complications. There were no cases of reoperation or perioperative mortality.
Conclusion
Camrelizumab plus albumin paclitaxel and carboplatin were found to be safe and effective in the neoadjuvant treatment of borderline resectable or unresectable locally advanced esophageal cancer. It was observed to improve the rate of curative resection without increasing perioperative complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanxi Cancer Hospital, Taiyuan, PR China.
ORCID-Profile: Shuangping Zhang
Förderung
- Wu Jieping Medical Foundation
- The Science and Education Cultivation Fund of the National Cancer and Regional Medical Center of Shanxi Provincial Cancer Hospital
Zitieren
APA
Chao, L., Liu, J., Chen, Y., Fan, Y., Guo, S., & Zhang, S. (2024). Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma. Thoracic Cancer, 15(8), 622-629. https://doi.org/10.1111/1759-7714.15232
Vancouver
Chao L, Liu J, Chen Y, Fan Y, Guo S, Zhang S. Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma. Thoracic Cancer. 2024;15(8):622-629. doi:10.1111/1759-7714.15232
BibTeX
@article{Chao2024,
author = {Chao, Li and Liu, Jianting and Chen, Yun and Fan, Yuhui and Guo, Shiping and Zhang, Shuangping},
title = {Benefits of camrelizumab plus carboplatin and albumin paclitaxel as induction therapy for locally advanced borderline resectable or unresectable esophageal squamous cell carcinoma},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {8},
pages = {622--629},
doi = {10.1111/1759-7714.15232}
}
EUVIMED